Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Severe Acute Respiratory Syndrome 1Mastocytosis 1Lymphoma 1Hypersensitivity 1COVID-19 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Rituximab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × BNT162 Vaccine × 1 year × Clear all
NCT05170399 2026-02-05

Vaccine Responses in Patients With B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 4 Recruiting
500 enrolled
Lymphoid

Lymphoma

NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡